J. Biol. Chem., Vol. 266, Issue 19, 12173-12179, 07, 1991

Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction

H Molina, C Brenner, S Jacobi, J Gorka, JC Carel, T Kinoshita and VM Holers
Howard Hughes Medical Institute Laboratories, Washington University School of Medicine, St. Louis, Missouri 63110.

The predicted amino acid sequence of human complement receptor 2 (CR2, CD21, C3d,g/Epstein-Barr virus receptor) and its genetic murine homologue are approximately 70% identical. The sequence of each consists of a linear array of 60-70 amino acid repeats designated short consensus repeats (SCRs). Although they share significant sequence identity, a major difference in the activities of these two proteins has been believed to be the ability of human, but not mouse, CR2 to mediate Epstein-Barr virus (EBV) infection of B lymphocytes. In order to formally address this question and to directly compare the activities of the CR2 protein of each species, we have expressed recombinant mouse CR2 (rMCR2) in a human K562 erythroleukemia cell line background. We have found that rMCR2 reacts with two previously described rat anti-MCR2 monoclonal antibodies (mAbs), 7G6 and 7E9, but not mAb 8C12, which recognizes only mouse complement receptor 1. rMCR2 rosettes with erythrocytes bearing mouse and human C3d,g and binds glutaraldehyde cross-linked human C3d,g with a similar Kd as human CR2 (HCR2). rMCR2 does not bind EBV. By using this observation and constructing chimeras bearing portions of MCR2 on a HCR2 background, we have been able to define unique sequences in HCR2 SCRs 1 and 2 important in the interaction with both mAb OKB7, which blocks EBV binding and infection, and with EBV. In addition, by using blocking peptides derived from HCR2 sequence, we have identified a second distinct region in SCR2 important in EBV binding. Therefore, within the first two SCRs of HCR2 are multiple distinct sites of interaction with EBV and with mAb OKB7.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. A. Young, X. S. Chen, V. M. Holers, and J. P. Hannan Isolating the Epstein-Barr Virus gp350/220 Binding Site on Complement Receptor Type 2 (CR2/CD21) J. Biol. Chem., December 14, 2007; 282(50): 36614 - 36625. [Abstract] [Full Text] [PDF]

				J. Ho, S. Moir, L. Kulik, A. Malaspina, E. T. Donoghue, N. J. Miller, W. Wang, T.-W. Chun, A. S. Fauci, and V. M. Holers Role for CD21 in the Establishment of an Extracellular HIV Reservoir in Lymphoid Tissues J. Immunol., June 1, 2007; 178(11): 6968 - 6974. [Abstract] [Full Text] [PDF]

				F. C. Hsiao, M. Lin, A. Tai, G. Chen, and B. T. Huber Cutting Edge: Epstein-Barr Virus Transactivates the HERV-K18 Superantigen by Docking to the Human Complement Receptor 2 (CD21) on Primary B Cells J. Immunol., August 15, 2006; 177(4): 2056 - 2060. [Abstract] [Full Text] [PDF]

				C. Fleischli, S. Verhaagh, M. Havenga, D. Sirena, W. Schaffner, R. Cattaneo, U. F. Greber, and S. Hemmi The Distal Short Consensus Repeats 1 and 2 of the Membrane Cofactor Protein CD46 and Their Distance from the Cell Membrane Determine Productive Entry of Species B Adenovirus Serotype 35 J. Virol., August 1, 2005; 79(15): 10013 - 10022. [Abstract] [Full Text] [PDF]

				D. Morikis and J. D. Lambris The Electrostatic Nature of C3d-Complement Receptor 2 Association J. Immunol., June 15, 2004; 172(12): 7537 - 7547. [Abstract] [Full Text] [PDF]

				J. Tabiasco, A. Vercellone, F. Meggetto, D. Hudrisier, P. Brousset, and J.-J. Fournie Acquisition of Viral Receptor by NK Cells Through Immunological Synapse J. Immunol., June 15, 2003; 170(12): 5993 - 5998. [Abstract] [Full Text] [PDF]

				H. L. Greenstone, F. Santoro, P. Lusso, and E. A. Berger Human Herpesvirus 6 and Measles Virus Employ Distinct CD46 Domains for Receptor Function J. Biol. Chem., October 11, 2002; 277(42): 39112 - 39118. [Abstract] [Full Text] [PDF]

				A. E. Prota, D. R. Sage, T. Stehle, and J. D. Fingeroth The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding PNAS, August 6, 2002; 99(16): 10641 - 10646. [Abstract] [Full Text] [PDF]

				J. M. Guthridge, K. Young, M. G. Gipson, M.-R. Sarrias, G. Szakonyi, X. S. Chen, A. Malaspina, E. Donoghue, J. A. James, J. D. Lambris, et al. Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface J. Immunol., November 15, 2001; 167(10): 5758 - 5766. [Abstract] [Full Text] [PDF]

				M. R. Sarrias, S. Franchini, G. Canziani, E. Argyropoulos, W. T. Moore, A. Sahu, and J. D. Lambris Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/220 J. Immunol., August 1, 2001; 167(3): 1490 - 1499. [Abstract] [Full Text] [PDF]

				K. M. Haan, A. Aiyar, and R. Longnecker Establishment of Latent Epstein-Barr Virus Infection and Stable Episomal Maintenance in Murine B-Cell Lines J. Virol., March 15, 2001; 75(6): 3016 - 3020. [Abstract] [Full Text]

				M. Barel, M. Le Romancer, and R. Frade Activation of the EBV/C3d Receptor (CR2, CD21) on Human B Lymphocyte Surface Triggers Tyrosine Phosphorylation of the 95-kDa Nucleolin and Its Interaction with Phosphatidylinositol 3 Kinase J. Immunol., March 1, 2001; 166(5): 3167 - 3173. [Abstract] [Full Text] [PDF]

				N. Ono, H. Tatsuo, K. Tanaka, H. Minagawa, and Y. Yanagi V Domain of Human SLAM (CDw150) Is Essential for Its Function as a Measles Virus Receptor J. Virol., February 15, 2001; 75(4): 1594 - 1600. [Abstract] [Full Text]

				L. Clemenza and D. E. Isenman Structure-Guided Identification of C3d Residues Essential for Its Binding to Complement Receptor 2 (CD21) J. Immunol., October 1, 2000; 165(7): 3839 - 3848. [Abstract] [Full Text] [PDF]

				K. J. Marchbank, C. C. Watson, D. F. Ritsema, and V. M. Holers Expression of Human Complement Receptor 2 (CR2, CD21) in Cr2-/- Mice Restores Humoral Immune Function J. Immunol., September 1, 2000; 165(5): 2354 - 2361. [Abstract] [Full Text] [PDF]

				E. Fernandez-Centeno, G. de Ojeda, J. M. Rojo, and P. Portoles Crry/p65, a Membrane Complement Regulatory Protein, Has Costimulatory Properties on Mouse T Cells J. Immunol., May 1, 2000; 164(9): 4533 - 4542. [Abstract] [Full Text] [PDF]

				M.-B. Villiers, C. L. Villiers, A.-M. Laharie, and P. N. Marche Amplification of the Antibody Response by C3b Complexed to Antigen Through an Ester Link J. Immunol., March 15, 1999; 162(6): 3647 - 3652. [Abstract] [Full Text] [PDF]

				S. Bouillie, M. Barel, and R. Frade Signaling Through the EBV/C3d Receptor (CR2, CD21) in Human B Lymphocytes: Activation of Phosphatidylinositol 3-Kinase via a CD19-Independent Pathway J. Immunol., January 1, 1999; 162(1): 136 - 143. [Abstract] [Full Text] [PDF]

				W. M. Prodinger, M. G. Schwendinger, J. Schoch, M. Kochle, C. Larcher, and M. P. Dierich Characterization of C3dg Binding to a Recess Formed Between Short Consensus Repeats 1 and 2 of Complement Receptor Type 2 (CR2; CD21) J. Immunol., November 1, 1998; 161(9): 4604 - 4610. [Abstract] [Full Text] [PDF]

				Y. Fang, C. Xu, Y.-X. Fu, V. M. Holers, and H. Molina Expression of Complement Receptors 1 and 2 on Follicular Dendritic Cells Is Necessary for the Generation of a Strong Antigen-Specific IgG Response J. Immunol., June 1, 1998; 160(11): 5273 - 5279. [Abstract] [Full Text] [PDF]

				C. J. Buchholz, D. Koller, P. Devaux, C. Mumenthaler, J. Schneider-Schaulies, W. Braun, D. Gerlier, and R. Cattaneo Mapping of the Primary Binding Site of Measles Virus to Its Receptor CD46 J. Biol. Chem., August 29, 1997; 272(35): 22072 - 22079. [Abstract] [Full Text] [PDF]